850176-30-6

ADL-5747 is a selective and orally active agonist of the δ-opioid receptor (DOR). By binding to the δ-opioid receptors, ADL-5747 activates these receptors, thereby playing a role in pain management pathways. ADL-5747 can be used for research into pain management mechanisms[1].

[1] Le Bourdonnec B, et al. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N, N-diethyl-3-hydroxy-4-(spiro [chromene-2, 4′-piperidine]-4-yl) benzamide (ADL5747)[J]. Journal of medicinal chemistry, 2009, 52(18): 5685-5702. DOI:10.1021/jm900773n